# BCB-214

Source: https://onco.cc/drugs/bcb-214/  
OnCo record `bcb-214` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BCB-214 is an experimental CAR T cell therapy from BrainChild Bio, at a stage the company does not state for glioblastoma and diffuse midline glioma.

## Summary

BCB-214 is a CAR T cell therapy (triple-targeting) from BrainChild Bio. A triple-targeting CAR T cell therapy against EGFR, B7-H3 and IL13Ralpha2, combined with the company's functional retention technologies and repeated intracerebroventricular dosing, designed to overcome tumour heterogeneity and the immunosuppressive tumour microenvironment. The company does not state its stage; it is aimed at glioblastoma and diffuse midline glioma. No clinical trial naming it is registered on ClinicalTrials.gov. The pipeline page gives no stage; no ClinicalTrials.gov study names BCB-214 (query.intr=BCB-214 returned 0 on 3 Nov 2026). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: BCB-214
- Modality: CAR T cell therapy (triple-targeting)
- Mechanism: A triple-targeting CAR T cell therapy against EGFR, B7-H3 and IL13Ralpha2, combined with the company's functional retention technologies and repeated intracerebroventricular dosing, designed to overcome tumour heterogeneity and the immunosuppressive tumour microenvironment.

## Sources

- BrainChild Bio: brainchildbio.com: https://www.brainchildbio.com/pipeline
- BrainChild Bio: brainchildbio.com: https://www.brainchildbio.com/pipeline

## Connected records

- targets: [B7-H3](https://onco.cc/targets/b7h3/), [EGFR](https://onco.cc/targets/egfr/)
- companies: [BrainChild Bio](https://onco.cc/companies/brainchild-bio/)

---
JSON: https://onco.cc/api/v1/entities/bcb-214.json